Skip to main content

Smith+Nephew CEO Deepak Nath to Join Reckitt Board as Independent Director

Tipranks - Fri Mar 6, 9:10AM CST

Claim 70% Off TipRanks Premium

Smith & Nephew Snats ( (SNN) ) has issued an update.

Smith+Nephew has disclosed that its Chief Executive Officer, Deepak Nath, will join the board of consumer health and hygiene group Reckitt Benckiser Group as an independent non-executive director from 1 April 2026. The appointment, announced on 5 March 2026 in line with UK listing rules, adds an additional high-profile external governance role for Nath, potentially broadening his strategic exposure and networks while he continues to lead the FTSE 100 medtech group.

The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith+Nephew is a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue, operating through Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, it now employs about 17,000 people, operates in more than 100 countries, generated $6.2 billion in sales in 2025, and is listed on both the London Stock Exchange and the New York Stock Exchange as a FTSE 100 constituent.

Average Trading Volume: 835,699

Technical Sentiment Signal: Buy

Current Market Cap: $15.17B

For an in-depth examination of SNN stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.